Page last updated: 2024-12-08

eilatine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

eilatine: isolated from the Red Sea purple tunicate Eudistoma sp.; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID149352
CHEMBL ID127811
SCHEMBL ID5048991
MeSH IDM0256387

Synonyms (11)

Synonym
CHEMBL127811
dibenzo[b,j]dipyrido[4,3,2-de:2,3,4-gh][1,10]phenanthroline
eilatin
eilatine
dibenzo(b,j)dipyrido(4,3,2-de:2',3',4'-gh)(1,10)phenanthroline
isoeilatin
120154-96-3
dibenzo[b,j]dipyrido[4,3,2-de:2',3',4'-gh][1,10]phenanthroline
SCHEMBL5048991
DTXSID40923249
3,13,16,26-tetrazaheptacyclo[13.11.1.12,10.04,9.019,27.020,25.014,28]octacosa-1(26),2,4,6,8,10(28),11,13,15,17,19(27),20,22,24-tetradecaene

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
" The importance of physicochemical properties of molecules in the development of orally bioavailable drugs has been recognized."( Drug-like properties: guiding principles for the design of natural product libraries.
Camp, D; Campitelli, M; Davis, RA; Ebdon, J; Quinn, RJ, 2012
)
0.38
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (6)

Assay IDTitleYearJournalArticle
AID51932Tested for the cytotoxicity against the repair deficient xrs-6 chinese hamster ovary cell line; ND is Not Determined1994Journal of medicinal chemistry, Oct-28, Volume: 37, Issue:22
Inhibition of topoisomerase II catalytic activity by pyridoacridine alkaloids from a Cystodytes sp. ascidian: a mechanism for the apparent intercalator-induced inhibition of topoisomerase II.
AID80703Tested for the cytotoxicity to inhibit replication assay against the human colon tumor cell line HCT1161994Journal of medicinal chemistry, Oct-28, Volume: 37, Issue:22
Inhibition of topoisomerase II catalytic activity by pyridoacridine alkaloids from a Cystodytes sp. ascidian: a mechanism for the apparent intercalator-induced inhibition of topoisomerase II.
AID227750Concentration required to reduce ethidium bromide fluorescence to 50% of control in presence of calf thymus DNA1994Journal of medicinal chemistry, Oct-28, Volume: 37, Issue:22
Inhibition of topoisomerase II catalytic activity by pyridoacridine alkaloids from a Cystodytes sp. ascidian: a mechanism for the apparent intercalator-induced inhibition of topoisomerase II.
AID211121Effect of dose dependent inhibition of TOPO II-catalyzed kDNA decatenation in vitro; ND is Not Determined1994Journal of medicinal chemistry, Oct-28, Volume: 37, Issue:22
Inhibition of topoisomerase II catalytic activity by pyridoacridine alkaloids from a Cystodytes sp. ascidian: a mechanism for the apparent intercalator-induced inhibition of topoisomerase II.
AID232295Differential cytotoxicity was determined from the ratio between BR1(IC50) and xrs-6 (IC50); ND is Not Determined1994Journal of medicinal chemistry, Oct-28, Volume: 37, Issue:22
Inhibition of topoisomerase II catalytic activity by pyridoacridine alkaloids from a Cystodytes sp. ascidian: a mechanism for the apparent intercalator-induced inhibition of topoisomerase II.
AID646600Antitrypanosomal activity against Trypanosoma brucei brucei2012Journal of natural products, Jan-27, Volume: 75, Issue:1
Drug-like properties: guiding principles for the design of natural product libraries.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (13)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's4 (30.77)18.2507
2000's8 (61.54)29.6817
2010's1 (7.69)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (7.69%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other12 (92.31%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]